Intrathecal Injection of Botulinum Toxin Type A has an Analgesic Effect in Male Rats CCI Model by Inhibiting the Activation of Spinal P2X4R

• DOI: 10.1007/s11064-023-03969-x
• Publication Date: 2023-06-19T17:01:34Z
• Authors: Wen-ming Zhou; Ze-yuan Lei; Yong-qiang Shi; Chao-yang Gong; Zhang Kai; Nan Wei; Lin-na Wang; Cheng-jun Zhang; Hai-hong Zhang
• Keywords: Male; Analgesics; Spinal Cord; Hyperalgesia; Animals; Neuralgia; Botulinum Toxins, Type A; Injections, Spinal; Rats

Purinergic receptor P2X4 (P2X4R) plays an essential role in neuropathic pain. However, the specific mechanism needs to be clarified. Botulinum toxin type A is a neurotoxin produced by Clostridium botulinum type A. This study found that intrathecal injection of botulinum toxin type A produced an excellent analgesic effect in a rat model of chronic constriction sciatic nerve injury and inhibited the activation of P2X4R, microglia, and astrocytes. The administration of a P2X4R activator can up-regulate the expression of P2X4R and eliminate the analgesic effect of intrathecal injection of botulinum toxin type A. In addition, we found that microglia and astrocytes in the spinal cord of rats injected with botulinum toxin type A were reactivated after administration of the P2X4R activator. Our results suggest that intrathecal injection of botulinum toxin type A has an analgesic effect in a rat model of chronic constriction sciatic nerve injury by inhibiting the activation of P2X4R in the spinal cord.